AngioDynamics Eyes Growth Despite Tariffs
AngioDynamics, Inc. (NASDAQ:ANGO) posted stronger-than-expected first-quarter results across its Med-Tech businesses and lifted its fiscal 2026 guidance.
Benzinga ·
Get all your news in one place.
100's of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100's of premium titles. One news app.
The Latest Breaking News from NanoKnife
AngioDynamics Posts Wider Q3 Loss On Higher Costs, Reaffirms FY22 Outlook
AngioDynamics Inc (NASDAQ:ANGO) has reported a Q3 FY22 adjusted EPS of $0.03, ahead of the consensus of $(0.01), and better than the consensus of $0.02 reported a year ago. Q3 sales increased 3.9% Y/Y to $73.97 million, missing the analyst consensus of $76.32 million. Endovascular Therapies net sales increased 14.5% to $38.1…
Benzinga ·
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Coverage From
Benzinga
Organisations
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Topics
Read news from The Economist, FT, and more,
with one subscription
with one subscription
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.
100+ trusted global sources.
